Stanford Cancer Institute shared on LinkedIn:
“Pamela N Munster, MD, will join the Stanford Cancer Institute as the inaugural associate director for early detection and interception research on August 1, 2026.
She will also assume a faculty appointment as a professor in the Stanford Medicine Division of Oncology.
As part of the Stanford Cancer Institute leadership team, she will work alongside Vivek Subbiah, in the Early Drug Development Program to expand Stanford’s capabilities in early-phase cancer clinical trials, which evaluate the effectiveness and safety of promising therapeutics and treatment strategies.
Munster has served as the principal investigator on multiple first-in-human early-phase clinical trials and leads National Institutes of Health (NIH)-funded laboratory research.
She is recognized for her leadership in translational oncology, which advances scientific discoveries into patient care, and precision oncology, where clinicians tailor treatment to the specific biology of a patient’s tumor.
‘Dr. Munster’s leadership in precision oncology, hereditary cancer, and cancer prevention aligns closely with the goals of our Early Drug Development Program,’ Steven Artandi, MD, PhD, director of the Stanford Cancer Institute, said.
‘With the complementary expertise of Dr. Munster and Dr. Subbiah, Stanford is positioned to expand viable treatment options for patients with advanced and treatment-resistant cancer.’
Welcome, Dr. Munster!
Read more: Stanford appoints new leader to expand impact in early drug development.”
Other articles about Pamela N Munster and Stanford Cancer Institute on OncoDaily.
